Paracrine Receives FDA Approval to Launch a U.S. Pivotal Trial in Patients With Hand Dysfunction Due to Diffuse Cutaneous Scleroderma January 25, 2022 by Businesswire [#item_full_content] Related Spread the word
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Portuguese
Russian
Spanish